Toth Financial Advisory Corp Trims Stock Position in Becton, Dickinson and Company $BDX

Toth Financial Advisory Corp trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 29.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,236 shares of the medical instruments supplier’s stock after selling 6,735 shares during the period. Toth Financial Advisory Corp’s holdings in Becton, Dickinson and Company were worth $2,457,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the last quarter. United Bank grew its stake in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after buying an additional 993 shares during the period. Marshall Wace LLP increased its holdings in shares of Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after buying an additional 6,058 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of a number of research analyst reports. The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. TD Cowen upped their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Barclays raised their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Bank of America decreased their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $185.67.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 11,869 shares of company stock worth $1,994,719. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $189.71 on Friday. The firm has a market capitalization of $52.27 billion, a PE ratio of 57.14, a price-to-earnings-growth ratio of 13.26 and a beta of 0.19. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The stock’s 50 day moving average price is $166.14 and its 200 day moving average price is $160.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.